Literature DB >> 6584917

Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans.

A F Stalenhoef, M J Malloy, J P Kane, R J Havel.   

Abstract

The metabolism of apolipoproteins B-48 and B-100 (apo B-48 and B-100) in large triglyceride-rich lipoproteins (300 to 1500 A in diameter) has been compared in three normal subjects and two subjects with genetically determined deficiency of lipoprotein lipase. The triglyceride-rich lipoproteins were obtained from a lipoprotein lipase-deficient donor 4 hr after a fat-rich meal in order to obtain chylomicrons (containing apo B-48) and very low density lipoproteins (VLDL) (containing apo B-100), whose properties had not been modified by the action of this enzyme. The triglyceride-rich lipoproteins were labeled with 125I and injected intravenously into recipients who had fasted overnight. In normal recipients, most of the apo B-48 was removed from the blood within 15 min, and most of the apo B-100 was removed within 30 min. In the lipoprotein lipase-deficient recipients, most of the injected apo B-100 remained in the blood for more than 8 hr; removal of apo B-48 was only slightly more rapid. In all subjects, only trace amounts of either protein were found in lipoproteins more dense than 1.006 g/ml. The results indicate that (i) the removal of the apo B of both chylomicrons and large VLDL from the blood is dependent upon the hydrolysis of their component triglycerides by lipoprotein lipase, and (ii) little or no apo B-48 of chylomicrons or apo B-100 of large VLDL is converted appreciably to low density lipoproteins (LDL). Our results suggest that the reported variability of the conversion of VLDL to LDL may be related to the size and composition of the particles secreted from the liver. The rapid production of remnant particles that are removed efficiently by the liver may minimize the opportunity for further reactions leading to the formation of LDL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6584917      PMCID: PMC345017          DOI: 10.1073/pnas.81.6.1839

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Fluorometric enzymatic determination of total cholesterol in serum.

Authors:  H Huang; J W Kauan; G G Guilbault
Journal:  Clin Chem       Date:  1975-10       Impact factor: 8.327

2.  Lipoprotein biosynthesis and metabolism.

Authors:  R J Havel
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

Review 3.  Quantification of triglyceride transport in blood plasma: a critical analysis.

Authors:  R J Havel; J P Kane
Journal:  Fed Proc       Date:  1975-12

4.  Metabolism of apoprotein B of plasma very low density lipoproteins in the rat.

Authors:  O Faergeman; T Sata; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

5.  Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans.

Authors:  T Sata; R J Havel; A L Jones
Journal:  J Lipid Res       Date:  1972-11       Impact factor: 5.922

6.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.

Authors:  A Pagnan; R J Havel; J P Kane; L Kotite
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

7.  Overproduction of a kinetic subclass of VLDL-apoB, and direct catabolism of VLDL-apoB in human endogenous hypertriglyceridemia: an analytical model solution of tracer data.

Authors:  R P Eaton; R C Allen; D S Schade
Journal:  J Lipid Res       Date:  1983-10       Impact factor: 5.922

8.  Slower removal of intestinal apolipoprotein B-48 than of apolipoprotein B-100 in severely hypertriglyceridemic subjects.

Authors:  P J Nestel; T Billington; N H Fidge
Journal:  Biochim Biophys Acta       Date:  1983-05-16

9.  Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia.

Authors:  R J Havel; T Kita; L Kotite; J P Kane; R L Hamilton; J L Goldstein; M S Brown
Journal:  Arteriosclerosis       Date:  1982 Nov-Dec

10.  Evaluation of the roles of lipoprotein lipase and hepatic lipase in lipoprotein metabolism: in vivo and in vitro studies in man.

Authors:  A Nicoll; B Lewis
Journal:  Eur J Clin Invest       Date:  1980-12       Impact factor: 4.686

View more
  34 in total

1.  Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects.

Authors:  D C Rubinsztein; J C Cohen; G M Berger; D R van der Westhuyzen; G A Coetzee; W Gevers
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase.

Authors:  M Shimada; S Ishibashi; T Inaba; H Yagyu; K Harada; J I Osuga; K Ohashi; Y Yazaki; N Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.

Authors:  R V Farese; M M Véniant; C M Cham; L M Flynn; V Pierotti; J F Loring; M Traber; S Ruland; R S Stokowski; D Huszar; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease).

Authors:  A S Wierzbicki; G F Watt; J Lynas; A F Winder; R Wray
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

Review 5.  Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Authors:  D C Chan; J Pang; G Romic; G F Watts
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

6.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

7.  Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia.

Authors:  D A Hardman; C R Pullinger; R L Hamilton; J P Kane; M J Malloy
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

8.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

9.  Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.

Authors:  A F Stalenhoef; M J Malloy; J P Kane; R J Havel
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

10.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.